nuclear factor of activated T cells 2 interacting proteinGenealiases: ESC2 · NIP45 · RAD60
Q-omics provides the consensus-scored NFATC2IP profile across patient tissues and cancer cell-line models. NFATC2IP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NFATC2IP is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NFATC2IP RNA expression shows 21,059 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where NFATC2IP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFATC2IP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFATC2IP survival associations across molecular data types. NFATC2IP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFATC2IP RNA expression–survival associations across cancer types. High NFATC2IP expression shows unfavorable associations in ACC, COAD, LGG, UVM, LIHC and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NFATC2IP RNA expression.
This table summarizes NFATC2IP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NFATC2IP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFATC2IP shows higher tumor expression in HNSC, KIRC, LIHC, KIRP, BLCA and STAD. The HNSC box plot shows higher NFATC2IP RNA expression in tumor versus normal tissue (log2 FC = +0.851, t-test p < 0.001).
This table shows molecular features associated with NFATC2IP in patient tissues and cancer cell lines. In patient samples, NFATC2IP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NFATC2IP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
